Captor Therapeutics (CTX) Q1 2026 earnings summary

Executive summary

• Advanced clinical and preclinical pipeline with multiple oncology and immunology assets, including viadrudomide and vratitoclax, progressing through key milestones.

• Continued R&D focus with ongoing clinical trials, formulation development, and regulatory preparations.

• Report covers the three months ended March 31, 2026, with comparative data for Q1 2025.

• The group operates in biotechnology R&D, focusing on targeted protein degradation.

• Shares are listed on the Warsaw Stock Exchange; recent capital increases were registered in April 2026.

Financial highlights

• Revenue from R&D services was 328k PLN in 1Q 2026, down from 2,606k PLN in 1Q 2025.

• Net loss for 1Q 2026 was -11,375k PLN, compared to -10,719k PLN in 1Q 2025.

• Cash and financial instruments totaled 17.9m PLN as of March 31, 2026, excluding proceeds from a share issue.

• Cash and cash equivalents at period end: PLN 2,348k, down from PLN 10,719k at year-end 2025.

• Diluted loss per share was PLN -2.10, compared to PLN -1.95 in Q1 2025.

Outlook and guidance

• March 2026 share issue raised PLN 65.6 million to support ongoing operations.

• Ongoing clinical study for viadrudomide in hepatocellular carcinoma.

• Vratitoclax preparations for clinical trials continue, with technical batch produced and clinical batch planned for Q3.

• Advanced discussions for new research collaborations and partnering agreements, especially for NEK7 degraders and other key projects.

• Management confident in sufficient resources for at least 12 months; seeking further collaborations, grants, or equity issuances.